Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Voronoi, Inc. (310210.KQ)
Incheon, RO
Voronoi, Inc., founded in 2015 and based in Incheon, South Korea, is a biotechnology company dedicated to the research, development, and identification of small molecule kinase inhibitors. Its extensive product pipeline addresses various medical needs. Key candidates include VRN01, an oral leucine-rich repeat kinase 2 (LRRK2) inhibitor, being developed for glioblastoma multiforme, brain cancer, and pancreatic cancer. Treatments for lung cancer are represented by VRN07, VRN06, and VRN11, while VRN08 and VRN10 are in development for breast cancer. Additionally, VRN02 targets rheumatoid arthritis and atopic dermatitis. The company's pipeline further encompasses VRN04-1 for autoimmune conditions, VRN04-2 for multiple sclerosis and amyotrophic lateral sclerosis (ALS), VRN13 for pulmonary arterial hypertension, and VRN14 for challenging solid tumors.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.35% | -1.37% | +1.06% | -14.20% | +21.87% | +33.49% | +171.52% | +677.43% | +1,073.42% | +1,073.42% | +1,073.42% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-40.3% Q1'26: -53.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,115.6%
-
EBIT margin Biotechnology: +0.0%-723.9%
-
ROIC Biotechnology: -16.1%-174.9% Q1'26: -275.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.9% Q1'26: +1.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.76× Q1'26: -0.42× (vs Q1'25)
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 3 EPS Ana. |
Dec 2027 3 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|
| Revenue |
—
|
7.51B
est: 14.73B (-49.0%)
|
34.00B
21.19B – 56.70B
+130.8% YoY
|
25.37B
3.00B – 65.00B
-25.4% YoY
|
| EBITDA |
-34.37B
|
-52.60B
est: -2.35B (-2,142.0%)
|
-5.41B
-9.03B – -3.37B
-130.8% YoY
|
-4.04B
-10.35B – -477.70M
+25.4% YoY
|
| EBIT |
-36.34B
|
-54.38B
est: -2.95B (-1,745.6%)
|
-6.80B
-11.34B – -4.24B
-130.8% YoY
|
-5.07B
-13.00B – -600.00M
+25.4% YoY
|
| Net Income |
-32.61B
est: -40.50B (+19.5%)
|
-48.02B
est: -32.37B (-48.4%)
|
-48.81B
-55.80B – -44.09B
-50.8% YoY
|
-52.13B
-69.40B – -42.47B
-6.8% YoY
|
| SGA |
16.08B
|
4.51B
est: 8.56B (-47.4%)
|
19.76B
12.32B – 32.96B
+130.8% YoY
|
14.74B
1.74B – 37.78B
-25.4% YoY
|
| EPS |
-1,860.33
est: -2,310.00 (+19.5%)
|
-2,610.52
est: -1,759.67 (-48.4%)
|
-2,653.67
-3,034.00 – -2,397.00
-50.8% YoY
|
-2,834.33
-3,773.00 – -2,309.00
-6.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sangjin Woo | Chief Operating Officer & Director | 134M | male |
| Hyuntae Kim | Chief Executive Officer & Director | 109M | male |
| Daekwon Kim | Chief Executive Officer & Director | 109M | male |
| Jaeyoung Ahn | CBO, President of Voronoi USA, Inc., & Head of U.S. Operations | 43M | male |
| Yin Zhang | Chief Medical Officer | — | — |
| Hosey Hwang | Director of Accounting | — | male |
| Sangjin Lee | Chief Financial Officer | — | male |
| Sunghwan Kim | Chief Science Officer & Director of Biology Research | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 310210.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
